Skip to main content

Prodesse Files for FDA OK for C. Difficile Assay

NEW YORK (GenomeWeb News) – Prodesse today said that it had filed for US Food and Drug Administration clearance of its molecular diagnostics assay for Clostridium difficle.

The Milwaukee, Wis.-based firm said that it had filed for 510(k) clearance of the ProGastro Cd Assay following clinical trials conducted at several clinical labs in the US. The assay is already being used for clinical diagnostics in Europe, and additional studies of the test are currently being conducted in the UK.

Prodesse Quality Officer Kristine Schraufnagel said that clinical trials on the ProGastro Cd Assay "easily met our clinical goals for sensitivity and specificity." The test provides results in as few as three hours, the firm said.

Prodesse also said that it has completed clinical trials on its ProParaFlu Assay and expects to submit a 510(k) filing with the FDA within the next 120 days.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.